Literature DB >> 30149763

An overview of cancer immunotherapeutic strategies.

Braira Wahid1,2, Amjad Ali2, Shazia Rafique3, Muhammad Waqar1,2, Muhammad Wasim4, Khansa Wahid5, Muhammad Idrees1,2,3,6.   

Abstract

Artificially boosting body's immune response is one of the most exciting, effective and promising advancements in the treatment of cancers. Cancer immunotherapeutics consist of variety of treatment approaches such as cytokine therapy, adoptive T-cell transfer therapy, and antibodies that stimulate innate and adoptive immune responses. In addition to this, development of HPV vaccine has paved way toward the development of other cancer vaccines. Checkpoint blockade inhibitors, for example, anti-programmed cell death protein 1 and anti-cytotoxic T-lymphocyte-associated antigen-4, chimeric antigen receptor T-cell therapy and monoclonal antibodies are emerging as other major breakthroughs that are highly effective against cancer. This review addresses the current status of immunotherapeutic strategies against cancer and provides baseline data for future research.

Entities:  

Keywords:  CAR T-cell therapy; cancer; cytokines; immunotherapy

Mesh:

Substances:

Year:  2018        PMID: 30149763     DOI: 10.2217/imt-2018-0002

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  8 in total

Review 1.  Nanoimmunoengineering strategies in cancer diagnosis and therapy.

Authors:  Robabehbeygom Ghafelehbashi; Melina Farshbafnadi; Niloofar Shokraneh Aghdam; Shahin Amiri; Mitra Salehi; Sepideh Razi
Journal:  Clin Transl Oncol       Date:  2022-09-08       Impact factor: 3.340

Review 2.  Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy.

Authors:  Maiko Matsushita; Mai Kawaguchi
Journal:  J Oncol       Date:  2018-10-25       Impact factor: 4.375

Review 3.  Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines.

Authors:  Jerri C Caldeira; Michael Perrine; Federica Pericle; Federica Cavallo
Journal:  Viruses       Date:  2020-04-27       Impact factor: 5.048

Review 4.  New Immunotherapeutic Approaches for Glioblastoma.

Authors:  Gustavo Ignacio Vázquez Cervantes; Dinora F González Esquivel; Saúl Gómez-Manzo; Benjamín Pineda; Verónica Pérez de la Cruz
Journal:  J Immunol Res       Date:  2021-09-13       Impact factor: 4.818

Review 5.  Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.

Authors:  Bing-Tao Zhai; Huan Tian; Jing Sun; Jun-Bo Zou; Xiao-Fei Zhang; Jiang-Xue Cheng; Ya-Jun Shi; Yu Fan; Dong-Yan Guo
Journal:  J Transl Med       Date:  2022-03-18       Impact factor: 5.531

6.  Analysis of Tryptophan and Its Main Metabolite Kynurenine and the Risk of Multiple Cancers Based on the Bidirectional Mendelian Randomization Analysis.

Authors:  Ran Li; Xuanyang Wang; Yuntao Zhang; Xiaoqing Xu; Lulu Wang; Chunbo Wei; Lin Liu; Ziqi Wang; Ying Li
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

7.  Anticancer and Immunomodulatory Activities of a Novel Water-Soluble Derivative of Ellipticine.

Authors:  Regiane Costa de Oliveira; Gemilson Soares Pontes; Aleksandr Kostyuk; Gabriel B Coutinho Camargo; Anamika Dhyani; Tetiana Shvydenko; Kostiantyn Shvydenko; Andriy Grafov
Journal:  Molecules       Date:  2020-05-01       Impact factor: 4.411

8.  A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis.

Authors:  Montserrat Lara-Velazquez; Jack M Shireman; Eric J Lehrer; Kelsey M Bowman; Henry Ruiz-Garcia; Mitchell J Paukner; Richard J Chappell; Mahua Dey
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.